In what scenario would you prefer weekly vs every 3 week carboplatin/paclitaxel for high grade serous ovarian cancer?

This is a great question without a simple answer. Let’s briefly review the pertinent data, followed by a discussion on how to use the information to consider weekly chemotherapy vs. a standard q 3-week (wk) chemotherapy regimen for primary advanced ovarian cancer.

There has been increasing interest i...

Based off both my practice and ICON 8 (Clamp et al., Lancet 2019), there is no scenario in which I prefer weekly carboplatin and paclitaxel over the Q3 week dosing. The only time I would consider giving weekly carboplatin and paclitaxel is when I have a patient who deeply desires treatment but is to...

This is a great question and there is a lovely discussion above. I think the key summary point is that the weekly carbo-paclitaxel (Mito-7) regimen is clearly not inferior, and can be used if the clinical scenario indicates. Many had raised concerns that the pharmacokinetics of this regimen would no...